Symposium
Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective
Friday, November 20, 2020
The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective was a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium was to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants learned about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.
This one-day symposium was held virtually.
Speakers:
- Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute
- Victor Ling, PhD, Terry Fox Research Institute
- Sohrab Shah, PhD, Memorial Sloan Kettering Cancer Center
- Dan Landau, MD, PhD, New York Genome Center
- Emile Voest, MD, PhD, Netherlands Cancer Institute
- Kathy McCoy, PhD, University of Calgary
- John Hilton, MD, Ottawa Health Sciences Center
- Grainne O’Kane, MD, Princess Margaret Cancer Centre
Target Audience for the Cancer Genomics and Tumor Immunotherapy Symposium:
- Oncologists: Medical, Radiation, Surgical
- Pathologists
- Clinical Geneticists
- Genetic Counselors
- Laboratory Directors
- Laboratory Technicians
- Oncology Nurses
- Bioinformaticians
- Basic and Translational Scientists
- Basic, Translational and Clinical Trainees
- Pharmaceutical Representatives
Topics discussed:
- AACR PROJECT GENIE – Integrating Genomics & Phenomics Through Standardized Curation of Real-World Data
- Terry Fox Marathon of Hope Comprehensive Cancer Centre Update
- Single Cell RNA Sequencing and Clinical Applications
- Molecular Residual Disease and ctDNA: Opportunities for Interception
- The Role of Tumor Organoids in the Evaluation of Immunotherapy
- Microbiome, Cancer and Inflammation
- Debate: This house believes that there are therapeutic strategies to turn "cold" tumors into "hot" tumor
Contact Us:
For more information regarding our program feel free to connect with us:
cgp@uhn.ca
(416) 946-2993
Links
Advanced Molecular Diagnostic LaboratoryPugh Lab
Princess Margaret Genomics Centre
Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective
Friday, November 16, 2018
The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.
This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:
MaRS Discovery District, 101 College Street, Toronto, ON, M5G 1L7
Speakers:
- Marco Marra, PhD, BC Cancer Agency
- Anthony Letai, MD, PhD, Dana-Farber Cancer Institute
- Nadeem Riaz, MD, Memorial Sloan Kettering Cancer Center
- Daniel De Carvalho, PhD, Princess Margaret Cancer Centre
- Stephen Schuster, MD, Hospital of the University of Pennsylvania
- Charles Drake, MD, PhD, Herbert Irving Comprehensive Cancer Center
- Evan Newell, PhD, Fred Hutchinson Cancer Research Center
- Bryan Coburn, MD, PhD, Toronto General Hospita
Target Audience for the Cancer Genomics and Tumor Immunotherapy Symposium:
- Oncologists: Medical, Radiation, Surgical
- Pathologists
- Clinical Geneticists
- Genetic Counselors
- Laboratory Directors
- Laboratory Technicians
- Oncology Nurses
- Bioinformaticians
- Basic and Translational Scientists
- Basic, Translational and Clinical Trainees
- Pharmaceutical Representatives
Topics discussed:
- Personalized Oncogenomics (POG)
- Augmenting Genomics with Functional Precision Medicine in Cancer
- The Cancer Genome's Influence on Immunotherapy
- Epigenetics and Circulating DNA
- CAR-T Therapy
- Personalized Cancer Vaccines
- The Intestinal Microbiota and Immunotherapy Responsivenes
FULL AGENDA & MEETING REGISTRATION:
Please visit our website to view the full symposium agenda and to register for this important event:
http://www.pm-genomics-io-symposium.caContact Us:
For more information regarding our program feel free to connect with us:
cgp@uhn.ca
(416) 946-2993
Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective
November 17, 2017
The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program and the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. This one-day symposium will include focused talks and panel discussions on cancer genomics and tumor immunotherapy. International, national, and local speakers will share with participants emerging therapies and technologies, novel genomic approaches for diagnosis, the clinical development of tumor-derived DNA as a biomarker for cancer, immunogenomic-based drug development, response, and resistant mechanisms to immune checkpoint therapy, and precision oncology for young people.
The target audience for this meeting includes academic and community oncologists, pharmaceutical leaders, regulatory agencies, basic and translational scientists and trainees. This symposium will provide a clinical and translational perspective on genomics and immunotherapy as it applies to precision cancer medicine at the point of care.
This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:
Date: Friday, November 17, 2017
Location: MaRS Discovery District, 101 College Street, Toronto, ON, M5G 1L7
Speakers:
- Dr. Max Diehn, MD, PhD (Stanford University)
- Meredith Irwin, MD (Hospital for Sick Children)
- Philippe Bedard, MD (Princess Margaret Cancer Centre)
- Trevor Pugh, PhD (Princess Margaret Cancer Centre)
- Adrian Sacher, MD (Herbert Irvine Comprehensive Cancer Center)
- Morag Park, PhD (McGill University)
- Frederick Locke, MD (Moffitt Cancer Center)
- Pamela L. Schwartzberg, MD, PhD (National Human Genome Research Institute)
Session Co-Chairs:
- Lillian Siu, MD (Princess Margaret Cancer Centre)
- Pam Ohashi, PhD (Princess Margaret Cancer Centre)
Topics discussed:
- Clinical Applications of High Throughput Sequencing-Based Circulating Tumor DNA Analysis
- Precision Oncology for Young People
- Update on the Cancer Genomics Program at Princess Margaret
- The Impact of Tumor Microenvironment on Immune Response in Triple Negative Breast Cancer
- Response and Resistance Mechanisms to Immune Checkpoint Therapy
- Immunogenomics as a Tool to Guide Rational Drug Development and Clinical Care
- CAR T Therapy
- Mechanisms of T Cell Exhaustion
FULL AGENDA & MEETING REGISTRATION:
Please visit our website to view the full symposium agenda and to register for this important event:
http://www.pm-genomics-io-symposium.caContact Us:
For more information regarding our program feel free to connect with us:
cgp@uhn.ca
(416) 946-2993
Applied Cancer Genomics Symposium
October 3rd 2014
The inaugural Applied Cancer Genomics Symposium was held on Friday, October 3rd, 2014 at the MaRS Discovery District to great success. It featured Canadian and international speakers presenting on four main topics: genomic sequencing in cancer, informatics, clinical applications of genomics and the future direction of precision medicine. Participants came from a variety of backgrounds, including healthcare (oncologists, pathologists, laboratory technicians), research, industry and members of the Princess Margaret Cancer Foundation. It was a well-attended inter-professional conference with 200 attendees, which brought together those interested in clinical genomics applications in oncology. One third of the registrants represented trainees, who attended the one-day event to learn more about the rapidly evolving genomic profiling technologies. Healthcare professionals felt the symposium was relevant to their disciplines, and that the talks provided a comprehensive perspective on the future of oncology research. The success of this event was made possible by the numerous sponsors, including The Princess Margaret Cancer Foundation. Click on any image to see a larger view.
